# A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

> **NCT00561015** · PHASE2 · COMPLETED · sponsor: **Tibotec BVBA** · enrollment: 52 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Telaprevir
- **DRUG:** Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00561015
- **Lead sponsor:** Tibotec BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-06
- **Final completion:** 2009-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2013-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561015, "A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00561015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*